FI3835298T3 - Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja - Google Patents

Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja Download PDF

Info

Publication number
FI3835298T3
FI3835298T3 FIEP20169240.7T FI20169240T FI3835298T3 FI 3835298 T3 FI3835298 T3 FI 3835298T3 FI 20169240 T FI20169240 T FI 20169240T FI 3835298 T3 FI3835298 T3 FI 3835298T3
Authority
FI
Finland
Prior art keywords
dione
piperidine
oxoisoindolin
piperazin
hydroxy
Prior art date
Application number
FIEP20169240.7T
Other languages
English (en)
Finnish (fi)
Inventor
Jie Fan
Yimin Qian
Wei He
Ke Liu
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Application granted granted Critical
Publication of FI3835298T3 publication Critical patent/FI3835298T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP20169240.7T 2019-12-12 2020-04-13 Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja FI3835298T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962947213P 2019-12-12 2019-12-12

Publications (1)

Publication Number Publication Date
FI3835298T3 true FI3835298T3 (fi) 2024-07-29

Family

ID=70289288

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20169240.7T FI3835298T3 (fi) 2019-12-12 2020-04-13 Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja

Country Status (11)

Country Link
US (2) US10800770B1 (https=)
EP (2) EP3835298B1 (https=)
JP (2) JP7662639B2 (https=)
KR (1) KR102942706B1 (https=)
CN (2) CN115003295B (https=)
CA (1) CA3164202A1 (https=)
DK (1) DK3835298T3 (https=)
ES (1) ES2986594T3 (https=)
FI (1) FI3835298T3 (https=)
MX (1) MX2022007155A (https=)
WO (1) WO2021118629A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
EP3932922A4 (en) 2019-02-25 2022-05-11 ShanghaiTech University SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
FI3835298T3 (fi) * 2019-12-12 2024-07-29 Accutar Biotechnology Inc Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja
WO2021133886A1 (en) * 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
CA3169011A1 (en) * 2020-02-25 2021-09-02 Xiaobao Yang Glutarimide skeleton-based compounds and uses thereof
AR123492A1 (es) 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
EP4289841A4 (en) * 2021-02-04 2025-02-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
WO2022187588A1 (en) * 2021-03-04 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of estrogen receptor with cereblon ligands
MX2023011166A (es) * 2021-03-29 2023-09-29 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
EP4377296A1 (en) 2021-07-26 2024-06-05 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
AU2022370021B2 (en) * 2021-10-22 2026-04-16 Gluetacs Therapeutics (Shanghai) Co., Ltd. Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
CN113816927B (zh) * 2021-11-23 2022-02-25 苏州国匡医药科技有限公司 一种arv-471中间体的制备方法
CN117229286A (zh) 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2024015409A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Chroman derivatives as estrogen receptor degraders
CN116751186B (zh) * 2022-12-23 2024-10-18 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
WO2024153025A1 (zh) * 2023-01-16 2024-07-25 南京明德新药研发有限公司 取代的苯并七元环化合物及其应用
CN119258223A (zh) * 2023-07-06 2025-01-07 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途
WO2025245408A1 (en) 2024-05-22 2025-11-27 Accutar Biotechnology Inc. Chroman-based compounds for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021710A1 (en) * 1996-10-28 2001-09-13 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129627A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129618A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
WO2003063659A1 (de) 2002-02-01 2003-08-07 Danny Bellens Ablageständer
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP3303326B1 (en) * 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
KR102674902B1 (ko) * 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
FI3835298T3 (fi) * 2019-12-12 2024-07-29 Accutar Biotechnology Inc Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja

Also Published As

Publication number Publication date
US20210221802A1 (en) 2021-07-22
JP2023506155A (ja) 2023-02-15
MX2022007155A (es) 2022-10-07
CA3164202A1 (en) 2021-06-17
US11261178B2 (en) 2022-03-01
WO2021118629A1 (en) 2021-06-17
DK3835298T3 (da) 2024-07-29
EP4420728A2 (en) 2024-08-28
EP3835298A1 (en) 2021-06-16
CN115003295B (zh) 2025-05-06
KR20220118460A (ko) 2022-08-25
ES2986594T3 (es) 2024-11-12
KR102942706B1 (ko) 2026-03-20
EP4420728A3 (en) 2024-10-30
CN120665056A (zh) 2025-09-19
US10800770B1 (en) 2020-10-13
JP2025081364A (ja) 2025-05-27
JP7662639B2 (ja) 2025-04-15
EP3835298B1 (en) 2024-06-26
CN115003295A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
FI3835298T3 (fi) Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja
RU2004112770A (ru) Производные имидазол-4-карбоксамида, их получение и применение для лечения ожирения
RU2368604C2 (ru) Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
RU2378268C2 (ru) Производные хиназолина в качестве ингибиторов тирозинкиназы
JPWO2021118629A5 (https=)
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
JP2013512899A5 (https=)
JPWO2019169123A5 (https=)
US20100022590A1 (en) Novel compounds
PL1706113T3 (pl) Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu
CR20230162A (es) Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
HUP9902808A2 (hu) 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása
JP2013537898A5 (https=)
JP2003506403A5 (https=)
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
JP2007513945A (ja) 体熱感、衝動調節障害および一般的な病状による人格変化の治療
RU2005131014A (ru) Азотосодержащие гетероциклические производные, содержащие 2, 6-дизамещенный стирил
DK0741724T3 (da) Neurobeskyttende chromanforbindelser
RU2012127272A (ru) Производные пирролидина
JP2003516975A5 (https=)
MX2021008321A (es) Composiciones farmaceuticas que comprenden (s)-4-(4-(4-(((2-(2,6-d ioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperaz in-1-il)-3-fluorobenzonitrilo y metodos para su uso.
KR910011817A (ko) 중추 신경계 약제로서 유용한 치환 시클로헥센
HUT65472A (en) Process for producing 3,4-dihydro-2(1h)-quinolone derivatives and pharmaceutical preparations containing them
RU2008143704A (ru) КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
RU2003116893A (ru) Новое применение объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина